Further, stages may overlap with a mixture of both acute and chronic facets of the disease.
Lyme disease remains difficult to diagnose, in part because the causative agent, Borrelia burgdorferi, is usually not easily cultured or directly observable from patients' specimens.
Currently available standard laboratory tests are not fully satisfactory in that they lack sensitivity and specificity and are not well standardized.
Underdiagnosis has proven to be a problem in parts of the country where it is not endemic or is relatively uncommon. Lyme disease can present with a wide variety of signs and symptoms, making it difficult for physicians who have little or no experience with it to make a correct diagnosis. On the other hand, in parts of the country where Lyme disease is well established and where there has been extensive publicity, patients with signs and symptoms suggestive of Lyme disease may be diagnosed inappropriately as having the disease when in fact they have some other disease resembling it.
Both aspects of this problem could be addressed by more sensitive, accurate, and inexpensive diagnostic tests. In general, serologic tests currently available do not detect some cases of early Lyme disease; conversely, in the later stages of the disease, tests are often too sensitive and less specific.
Once diagnosed, the manifestations of Lyme disease appear to be potentially treatable with a variety of antibiotics. The optimal regimen, including choice of drug, dose, route of administration, and length of therapy, has yet to be determined. Further clarification is also needed to determine the best method of treating disease sequelae at both early and late stages of Lyme disease.
Recent studies seem to indicate that tetracyclines or ceftriaxone may be superior to penicillin.
Oral tetracycline administration is typically effective in treating early erythema migrans, but once arthritis or neurologic manifestations have developed, high-dose parenteral treatment is recommended, although the effect on neurologic symptoms has not yet been proven. In the absence of long-term observations, it is not clear that oral administration of drugs alone can effect a cure, prevent further complications, or forestall evolution to a chronic disease state. o Utility of prophylactic antibiotics in exposed individuals from endemic areas.
RESEARCH GOALS AND SCOPE

MECHANISM OF SUPPORT
Applications considered appropriate responses to this RFA are the traditional research project grants (R01). Approximately $1,500,000 in total costs per year for 3 to 5 years will be committed by the NIAMS specifically to fund applications that are submitted in response to this RFA.
Approximately seven awards are expected to be made for this RFA.
The funding level for this RFA is dependent on the receipt of a sufficient number of applications of high scientific merit. The total project period for applications submitted may not exceed five (5) years. The earliest possible start date for the initial awards will be September 30, 1991.
Although there are provisions for this program in the financial plans of the NIAMS, award of grants pursuant to this RFA is contingent upon the availability of funds for this purpose.
Applications may receive secondary assignment, when appropriate, to other institutes of the NIH. Non-profit and for-profit institutions, as well as foreign and domestic institutions, are eligible to apply.
This RFA is a one-time solicitation. Future unsolicited competing renewal applications that result from this current RFA will compete as research project applications with all other investigatorinitiated applications and be reviewed by a standing Division of Research Grants study section.
In order to facilitate program planning and development, and to promote research interactions, the NIAMS intends to organize annual meetings of Principal Investigators and other key staff members of NIAMS-supported Lyme disease research projects. Funds for travel to these meetings (in Bethesda, Maryland) must be included in each year of the budget.
SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS
NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them.
This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed populationbased studies, a clear compelling rationale should be provided.
The composition of the proposed study population must be described in terms of gender and racial/ethnic group. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 in Section 2, A-D of the Research Plan AND summarized in Section 2, E, Human Subjects. Applicants/offerors are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans (including American Indians or Alaskan Natives), Asian/Pacific Islanders, Blacks, Hispanics).
The rationale for studies on single minority population groups should be provided.
For the purpose of this policy, clinical research includes human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials.
The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded.
However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants.
For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign population groups to the United States' populations, including minorities.
If the required information is not contained within the application, the application will be returned.
Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application.
All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not award grants or cooperative agreements that do not comply with these policies.
REVIEW PROCEDURES AND CRITERIA
REVIEW PROCEDURES
Applications will be reviewed initially by the Division of Research Grants for completeness and will be assigned to a special NIAMS review group. Evaluation for responsiveness to the RFA is an NIAMS program staff function. Applications that are judged non-responsive will be returned to the applicant but may be submitted as investigator-initiated applications at the next receipt date.
If the number of applications submitted is large compared to the number of awards to be made, the NIH will conduct an administrative review (triage) to eliminate those that are clearly not competitive. The NIH will withdraw from further competition those applications judged to be noncompetitive and notify the applicant and institutional business official.
Those applications judged to be both responsive and competitive will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate initial review group convened by the NIAMS Review Branch. The second level of review will be conducted by the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council.
REVIEW CRITERIA
Applications responsive to this competitive solicitation will be reviewed in accordance with the following criteria:
1. Extent of relevance of the proposed research to the aims of the RFA.
2. Scientific merit of the proposed approach, including the accuracy and quality of the methodological approach and the research design. Familiarity with the proposed techniques should be demonstrated, e.g., by presentation of preliminary data.
3. Expertise and qualifications of the Principal Investigator and proposed staff and/or collaborators to perform the proposed research.
Documentation of the adequacy of the facilities and resources.
The review group will critically examine the proposed budget and recommend an appropriate budget for each approved application.
APPLICATION PROCEDURES
The research grant application form PHS 398 (revised 10/88) must be used in applying for these grants. This form is available at most institutional business offices and from the Office of Grants Applications must be received by June 17, 1991. If an application is received after that date it will be returned to the applicant.
If the application submitted in response to this RFA is substantially similar to a research grant application already submitted to the NIH for review, but has not yet been reviewed, the applicant will be asked to withdraw either the pending application or the new one. Simultaneous submission of identical applications will not be allowed, nor will essentially identical applications be reviewed by different review committees. Therefore, an application cannot be submitted in response to this RFA that is essentially identical to one that has already been reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique.
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent by May 1, 1991. This letter should include the name of the institution, any other participating institutions, the Principal Investigator and other key investigators, and a descriptive title. Such a letter of intent is not binding and will not enter into the review of any application subsequently submitted, nor is it a necessary requirement for application. Letters of intent are requested solely for review planning purposes.
They allow NIAMS staff to estimate the potential review workload and to avoid possible conflict of interest in the review. NIAMS staff will not provide responses to such letters.
Letters of Intent are to be submitted to:
Dr. Tommy L. Broadwater
